Incidence of Atrophic Gastritis and Intestinal Metaplasia in Patients with <i>Helicobacter Pylori</i> Positive Duodenal Ulcer and Non-ulcer Dyspepsia
PDF
Cite
Share
Request
Research
P: 272-279
September 2019

Incidence of Atrophic Gastritis and Intestinal Metaplasia in Patients with Helicobacter Pylori Positive Duodenal Ulcer and Non-ulcer Dyspepsia

Med J Bakirkoy 2019;15(3):272-279
1. Esenyurt Üniversitesi, Memorial Şişli Hastanesi, Hematoloji ve Kemik İliği Nakil Merkezi, İstanbul, Türkiye
2. İstanbul Üniversitesi-Cerrahpaşa Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Gastroenteroloji Bilim Dalı, İstanbul, Türkiye
No information available.
No information available
Received Date: 30.03.2019
Accepted Date: 12.06.2019
Publish Date: 03.09.2019
PDF
Cite
Share
Request

ABSTRACT

Objective:

Helicobacter pylori was considered to be responsible for chronic atrophic gastritis and intestinal metaplasia. The frequency of coexistence of these three lesions and their relationship with H. pylori was the basis of our study.

Methods:

Therefore, data were collected to compare the incidence of atrophic gastritis and intestinal metaplasia with the same group of patients with H. pylori (+) positive duodenal ulcer and non-ulcer dyspepsia. The aim of this study was to investigate the effect of H. pylori (+) positivity on the incidence of atrophic gastritis and intestinal metaplasia. Positivity of atrophic gastritis and intestinal metaplasia was discussed in terms of statistical significance.

Results:

In our study H. pylori (+) positive group and 40-59 years of age, it was more frequent in the group of H. pylori (-) negative. There was no significant difference between the two groups in the group with positive antral gastritis between 40 and 59 years. There was no difference between the control group and the control group. Intestinal metaplasia was not detected according to the age groups.

Conclusion:

H. pylori was found to be effective on the development of duodenal ulcer, atrophic gastritis, intestinal metaplasia.

Keywords: Helicobacter pylori, duodenal ulcer, atrophic gastritis, intestinal metaplasia

References

1
Dooley CP. Background and historical considerations of Helicobacter pylori. Clin N Am 1993;22:1-19.
2
Blaser MJ. Gastric Campylobacter-like organisms, gastritis and peptic ulcer disease. Gastroenterology 1987;93:371-83.
3
Hui WM, Lam SK, Chau PY, Ho J, Lui I, Lai CL, et al. Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 1987;32:1255-60.
4
Recavarren-Arce S, León-Barúa R, Cok J, Rodríguez C, Berendson R, Gilman RH, et al. Low prevalence of gastric metaplasia in the duodenal mucosa in Peru. J Clin Gastroenterol 1992;15:296-301.
5
Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 19834;1:1273-5.
6
Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
7
Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
8
NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-9.
9
Williams MP, Pounder RE. Helicobacter pylori: from the benign to the malignant. Am J Gastroenterol 1999;94:11-6.
10
Mégraud F. Epidemiology of Helicobacter pylori infection. Gastroenterol Clin North Am 1993;22:73-88.
11
Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21:205-14.
12
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
13
Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9:59-69.
14
Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-40.
15
Gisbert JP, Gonzalez L, de Pedro A, Valbuena M, Prieto B, Llorca I, et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 2001;36:717-24.
16
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
17
Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998;93:574-8.
18
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment Pharmacol Ther 1996;10:251-61.
19
Lee A, Fox J, Hazell S. Pathogenicity of Helicobacter pylori: a perspective. Infect Immun 1993;61:1601-10.
20
Goodwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am 1993;22:5-19.
21
Malhotra SL. Peptic ulcer in İndia and its aetiology. Gut 1964;5:412-16.
22
Marshall AG, Hutchinson EO, Honisett J. Heredity in common diseases. A retrospective survey of twins in a hospital population. Br Med J 1962;1:1-6.
23
Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
24
Malfertheiner P, Domínguez-Muñoz JE. Rationale for eradication of Helicobacter pylori infection in duodenal ulcer disease. Clin Ther 1993;15 Suppl B:37-48.
25
Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut 1992;33:16-20.
26
Rugge M, Di Mario F, Cassaro M, Baffa R, Farinati F, Rubio J Jr, et al. Pathology of the gastric antrum and body associated with Helicobacter pylori infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia? Histopathology 1993;22:9-15.
27
Craanen ME, Blok P, Dekker W, Ferwerda J, Tytgat GN. Subtypes of intestinal metaplasia and Helicobacter pylori. Gut 1992;33:597-600.
28
Lam SK, Hui WM, Ching CK. Peptic ulcer. Bockus Gastroenterology, 5th edition. Philadelphia: WB Saunders Company 1995;700-748.
29
Cover TL, Glupczynski Y, Lage AP, Burette A, Tummuru MK, Perez-Perez GI, et al. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995;33:1496-500.
30
Lanas AI, Remacha B, Esteva F, Sáinz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124-33.
31
Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002;97:2950-61.
32
Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009;30:791-815.
33
Sari YS, Sander E, Erkan E, Tunali V. Endoscopic diagnoses and CLO test results in 9239 cases, prevalence of Helicobacter pylori in Istanbul, Turkey. J Gastroenterol Hepatol 2007;22:1706-11.
34
Salih BA, Abasiyanik MF, Bayyurt N, Sander E. H pylori infection and other risk factors associated with peptic ulcers in Turkish patients: a retrospective study. World J Gastroenterol 2007;13:3245-8.
35
Umit H, Unsal G, Tezel A, Soylu AR. Helikobakter pilori infeksiyonu ve benign gastroduodenal hastalıklar, Trakya bolgesi verileri. Trakya Universitesi Tıp Fakultesi Dergisi 2010;27:400-3.
36
Telaku S, Tanrıverdi T, Hatemi G, Doğusoy G, Goksel S, Uzunismail H. Helicobacter pylori negatif duodenal ülser artıyor mu? Endoskopi 2003;14:85-90.
37
Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
38
Genta RM. Atrophy, acid suppression and Helicobacter pylori infection: a tale of two studies. Eur J Gastroenterol Hepatol 1999;11:43-5.
39
Calabrese C, Di Febo G, Brandi G, Morselli-Labate AM, Areni A, Scialpi C, et al. Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Ital J Gastroenterol Hepatol 1999;31:359-65.
40
Vandenplas Y, Badriul H. Helicobacter pylori infection. Chung-Hua Min Kuo Hsiao Erhk’o I Hsueh Hui Tsa Chi 1999;40:212-24.
41
Satoh K, Kihira K, Kimura K, Sugano K. Changes in the severity of atrophic gastritis after Helicobacter pylori eradication. Nihon Rinsho 1999;57:185-90.
42
Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236-40.
43
Zhang L, Yang L, Zheng X. A study of Helicobacterium pylori and prevention and treatment of chronic atrophic gastritis. J Tradit Chin Med 1997;17:3-9.
2024 ©️ Galenos Publishing House